Ticker: HUM
Report date: July 29, 2026
Release / call: 6:00 a.m. / 8:00 a.m. ET (humana.gcs-web.com)
Humana’s second-quarter report is primarily a medical-cost and forward-margin test, not an EPS event.
The stock has rallied sharply as investors have become more confident that Medicare Advantage utilization is stabilizing and that Humana can rebuild margins after its 2026 Star Ratings setback. Recent results from UnitedHealth, Elevance and Centene have generally reinforced the improving medical-cost narrative. The burden on Humana is now to demonstrate that:
A modest headline beat with unchanged guidance may not be enough by itself. At roughly $389, HUM trades only about 9% below its 52-week high, and was already above the $344 median analyst target shown on Humana’s investor-relations site as of July 20. (investing.com)
| Metric | Q2 expectation / prior guidance |
|---|---|
| Adjusted EPS consensus | $7.22 mean; $7.42 median |
| GAAP EPS consensus | $7.19 mean |
| Revenue consensus | $40.61 billion |
| Insurance benefit ratio | Company guided to slightly above 91% |
| FY26 adjusted EPS guidance | At least $9.00 |
| FY26 adjusted EPS consensus | $8.94 mean; $9.05 median |
| FY26 Insurance benefit ratio | 92.75% ±25 bps |
| FY26 revenue guidance | At least $160 billion |
| FY26 individual MA growth | Approximately 25% |
Consensus figures are from Humana’s investor-relations estimate page. (humana.gcs-web.com)
The unusual earnings seasonality is worth emphasizing: consensus calls for positive Q2 earnings, roughly breakeven Q3 earnings and a large adjusted loss in Q4. Consequently, the fact that Q1 adjusted EPS of $10.31 already exceeded Humana’s full-year floor is not an error—it reflects the severe second-half seasonality created by benefit timing, the 2026 Stars headwind and the structure of Humana’s guidance. (policy.humana.com)
Humana reported a Q1 Insurance benefit ratio of 89.4%, slightly better than its “just under 90%” guide. Management said early indicators—including hospital admissions, pharmacy claims, risk scores and emerging medical claims—were running in line with or better than expectations. It nevertheless maintained a conservative reserve posture because of the scale of new-member growth. (policy.humana.com)
Q2 should provide a much more complete view of the 2026 book. The key questions are:
A benefit ratio at or below 91% would be clearly constructive against guidance for “slightly above 91%,” particularly if management attributes the result to current-year cost trends rather than reserve releases.
A ratio around 91%–91.3% should be broadly acceptable if the new-member cohort remains stable and full-year guidance is maintained.
A ratio materially above 91.5%, or language suggesting claims have worsened as they matured, would challenge the recovery narrative.
The earnings quality matters more than the precise EPS number. Investors should prefer a $7.30 result driven by sound current-period medical costs over a higher EPS figure dependent on prior-period reserve development or below-the-line items.
Recent managed-care earnings have generally pointed toward moderating medical-cost pressure:
That backdrop lowers the probability of a broad utilization shock. But it does not remove Humana-specific risk. Humana is unusually concentrated in Medicare Advantage, added more than one million individual MA members entering 2026, and is absorbing a company-specific quality-bonus revenue headwind.
The peer results therefore make a poor Humana print harder to explain away as an industry phenomenon.
At Q1, management said 2027 Medicare Advantage funding remained below medical-cost trend and indicated that Humana would adjust benefits and potentially its geographic footprint. Its priorities were explicit:
Investors should listen for additional detail now that the 2027 bid process is complete.
The best outcome would be commentary that Humana can produce meaningful 2027 margin expansion with manageable retention pressure. The risk is that benefit cuts needed to restore profitability cause more enrollment losses or adverse selection than management currently expects.
Humana has said it remains confident it can return to top-quartile Star Ratings performance for bonus year 2028, while acknowledging that final thresholds are outside its control. Management specifically promised a more complete Q2 update after the hybrid-measure season concluded.
Investors should look for quantifiable progress in:
The Stars recovery is critical because the 2026 earnings collapse is largely a revenue problem created by lost quality bonuses. A credible recovery could materially expand earnings in 2028; another disappointing ratings cycle would weaken the central long-term investment thesis.
Management does not need to guarantee the October ratings outcome, but it should be able to explain whether internal performance is tracking above, at or below the levels assumed in the 2028 margin target.
CenterWell’s Q1 revenue increased substantially, but segment profitability declined. Management attributed the weakness to several factors expected to normalize or reverse later in the year, including:
Humana maintained full-year CenterWell guidance of:
The report should demonstrate that Q1 was not the beginning of a sustained margin deterioration. Watch for:
Strong revenue growth without a path to better margins would diminish the value of CenterWell as Humana’s earnings-diversification engine.
In June, Humana agreed to sell all or substantially all of its minority interest in Gentiva for approximately $900 million. The transaction is expected to close in Q3, with proceeds intended for general corporate purposes and no material expected effect on 2026 earnings. (humana.gcs-web.com)
That provides useful liquidity because Humana has meaningful future capital requirements tied to its primary-care partnership with Welsh Carson. Its 2025 10-K estimated the first two clinic cohorts at approximately $1.0 billion–$1.5 billion, with total potential purchases across existing cohorts estimated at $3 billion–$5 billion over a multiyear period. (humana.gcs-web.com)
Investors should look for:
A major buyback announcement is unlikely to be the priority; balance-sheet resilience and funding strategic obligations should come first.
This would validate both the near-term utilization thesis and the longer-term 2028 earnings recovery.
This would be operationally adequate, although the stock reaction could be muted because the shares already discount substantial improvement.
Given the stock’s rebound, even a guidance reaffirmation could be received poorly if it is accompanied by weaker underlying medical-cost commentary.
The setup is constructive but demanding. Favorable peer results and Humana’s Q1 indicators suggest a reasonable chance of an in-line or better medical-cost report. However, the stock has moved from pricing a severe earnings impairment to pricing a credible multiyear recovery.
The most important signal will not be whether adjusted EPS beats $7.22 by a few cents. It will be whether Q2 provides convincing evidence that Humana can absorb its rapid membership growth, protect 2026 guidance, expand margins through the 2027 bid cycle and restore Stars-driven earnings power by 2028.